VEEV

Sales of 100 shares of Veeva (entire position); 200 shares of Procore and 320 Nutanix-Total Sales of Purchase of 300 shares of UiPath; 500 Shares of Nu Holdings; 633 shares of Pagaya; 400 shares of SentinelOne and 30 shares of Zscaler As we indicated in the post we sent on Thursday, we decided to make…

To access this post, you must subscribe.

Read More

Portfolio Change

Sale of 140 shares of Impinj (Entire Position) Purchase of 200 shares of Global One and 100 shares of Veeva We are making some portfolio changes in the Ticker Target High Growth Portfolio. We are selling our position in Impinj. The shares have been a yo-yo in the period since we have owned them. At…

To access this post, you must subscribe.

Read More

There have been lots of earnings the past few days, and some other news as well. Now, if only ChatGPT was up to the task…I have to confess as enthused as I am about GenerativeAI, it sometimes can compose the most peculiar sentences. I actually had to try to explain to it the difference between…

To access this post, you must subscribe.

Read More

Summary Veeva is one of the leading software providers to life sciences vertical. Recently growth has slowed, mainly a function of saturation in the company’s historic core of providing CRM solutions to the pharma industry. The company is in the process of moving its CRM solution to its own platform Vault, and this is likely…

To access this post, you must subscribe.

Read More

We finally pulled the trigger on a portfolio rebalance, eliminating our position in the shares of Veeva, and adding to our holding of Upstart. Overall, the transaction reduced our margin balance by a minimal level of just over $600. Our margin balance is as high as I find comfortable given the vicissitudes that market has…

To access this post, you must subscribe.

Read More

I am sure that subscribers will recognize that the last few days have seen a rather substantial pull-back in high growth tech names. Some losses have been greater than others. None of the valuation contraction has been based on some particular changes in the outlook for growth names, or their overall operational performance. We will…

To access this post, you must subscribe.

Read More

It can be daunting to write reviews on the quarterly performance of all the names that we try to follow at Ticker Target. Fortunately, when  earnings are well received, your writer doesn’t feel quite as stressed to deliver some kind of hasty commentary. And it is helpful to know that the crop of earnings that…

To access this post, you must subscribe.

Read More

Several software companies reported their results on, Sept. 1. 2021. Almost all of the results were upsides; in some cases the shares responded positively, in other cases not so much. I try not to get particularly focused on how shares respond to quarterly announcements as there are so many variables that go into  setting short-term…

To access this post, you must subscribe.

Read More

Earlier today, we made another change in our high-growth portfolio. We sold about 50% of our position in Atlassian-132 shares at $240.09.  This sale raised about $31,685.  Atlassian is a great company with a long runway of growth. But the shares have gained 25% in the last month. Part of that gain probably relates to…

To access this post, you must subscribe.

Read More

After a record setting November for many equity indices, December has opened with a bit of a pause-particularly so for high-multiple, high growth IT names.  The dreaded sector rotation came and went in a couple of weeks, leading to a noticeable rally. I would be surprised if December turned out to be quite so ebullient…

To access this post, you must subscribe.

Read More